Publication:
Retrospective analysis of clinical efficacy of erlotinib in patients with non-small cell lung cancer

No Thumbnail Available

Date

2015-03-01

Authors

ÖZKAYA, GÜVEN
Ayyıldız, Aylin
Kanat, Özkan
Deligönül, Adem
Gürsoy, Vildan

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Derman Medical Publ

Research Projects

Organizational Units

Journal Issue

Abstract

Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib as second-, third-, and fourth-line treatment for Turkish patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity were retrospectively analyzed. Results: We observed no complete response, partial responses were observed in 7 (17.9%) patients, and 16 (41 Ph) patients had stable disease. The median progression -free survival was 242 days (95% CI 51-224), and the median overall survival (OS) was 377 days (950/0 Cl 291462). The median 05 of females was significantly better than male patients (470 vs. 271 days, p=0.046). The treatment was generally well tolerated. The most common side effect was skin rash (4105). Discussion: Erlotinib was safe and effective in treating Turkish patients with advanced NSCLC who had been previously treated with the standard chemotherapy.

Description

Keywords

Molecularly targeted therapies, Inhibitors, Carcinoma, Mutations, Safety, Focus, Erlotinib, Non-small cell lung cancer, Targeted therapy, Science & technology, Life sciences & biomedicine, Medicine, general & internal, General & internal medicine

Citation

0

Views

0

Downloads

Search on Google Scholar